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Persistent, generalized lymphadenopathy (PGL) has been
defined as the occurrence of lymphadenopathy involving two or more
extra-inguinal sites, of at least three months' duration, in the
absence of any known intercurrent illness known to cause lymphade-
nopathy. Morphologically, the nodes exhibit a characteristic
exuberant follicular hyperplasia, with disorganization and disrup-
tion of the reactive follicles. We began a study of the natural
history of PGL in homosexual men from Los Angeles in 1983; 51 patients
have now been studied, and form the basis for this report. All men
were homosexual or bisexual, and all have history of receptive anal
intercourse, promiscuous and anonymous sexual contact, with a median
of 200 life-time male sexual partners. All patients had history of
illicit "recreational" drug abuse, including marijuana, cocaine,
amyl nitrite, and amphetamine.
The initial symptoms of illness included fever (47%),
night sweats (35%), headache with photophobia (18%), and extreme
fatigue and malaise (53%). Most patients first noted the onset of
lymphadenopathy after the onset of fever and malaise. In time,
many patients experienced a resolution of fever, headache, sweats
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and malaise, while no patient has had resolution of lymphadenopathy.
The mean T4:T8 ratio of our PGL patients was 0.57 (range
0.2-1.2; normal of 0.9-2.9). The majority of patients were also
found to have polyclonal hypergammaglobulinemia.
Presence of antibody to HTLV-III was found in 96% of the
PGL patients, while live virus could be cultured from peripheral
blood lymphocytes in 28/44 (64%). Of 31 well, asymptomatic homosex-
ual male control patients, 17 (55%) had antibody to HTLV-I1I, and 3/9
had live virus cultured from blood. Of 40 heterosexual asymptomatic
controls, none had antibody to HTLV-III.
In time, one of our PGL patients evolved to develop a
high-grade, B-cell lymphoma, a finding which prompted our study of
malignant lymphoma occurring in homosexual men, as part of the current
epidemic of AIDS. We have studied 27 such patients, diagnosed since
1982. High-grade, B-cell lymphomas were found in 22 (B-cell immuno-
blastic sarcoma, or small non-cleaved lymphoma), while low-grade
lymphomas were found in five. Antibody to HTLV-III was present in
13/15 (87%) with high-grade disease, and in 2/5 (40%) with low-grade
types (p=.07). In contrast, only one of ll (9%) "control" hetero-
sexual patients, with identical, high-grade lymphomas, diagnosed in
our Institution since 1980 had antibody to HTLV-III (p<.001). Of the
homosexual lymphoma patients, 85% presented with disease in extra-
nodal sites, including central nervous system, and rectum. During
the course of disease, 44% of the group experienced disease within
the central nervous system. A reversal of T4:T8 lymphocytes in the
blood was present in 81%. Despite multi-agent chemotherapy, the
median survival of these patients was eight months, with death due
to underlying lymphoma in the majority. The AIDS-related lymphomas
are extra-nodal, high-grade, B-cell tumors, associated with HTLV-III.
